News & Updates
Filter by Specialty:
Pemafibrate superior to conventional fibrates in T2DM
Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.
Pemafibrate superior to conventional fibrates in T2DM
01 Oct 2022
Alcohol consumption ups risk of CVD, all-cause mortality in men
Recent evidence suggests that drinking alcoholic beverages is associated with cardiovascular diseases (CVD), including coronary artery disease (CAD), and all-cause mortality.
Alcohol consumption ups risk of CVD, all-cause mortality in men
01 Oct 2022
Deucravacitinib bests placebo, apremilast in moderate-to-severe plaque psoriasis
Treatment with deucravacitinib achieves better efficacy than placebo and apremilast in patients with moderate-to-severe plaque psoriasis, while also yielding a good safety profile, reports a recent study.
Deucravacitinib bests placebo, apremilast in moderate-to-severe plaque psoriasis
01 Oct 2022
Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
Among patients with type 2 acute myocardial infarction (AMI), the absence of standard modifiable cardiovascular risk factors (SMuRF) appears to worsen poor outcomes, such as mortality, stroke, and major adverse cardiovascular and cerebrovascular events (MACCE), a new study has found.
